Oruka Therapeutics (NASDAQ:ORKA) Announces Quarterly Earnings Results

Oruka Therapeutics (NASDAQ:ORKA) announced its quarterly earnings results on Wednesday. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04, FiscalAI reports.

Oruka Therapeutics Price Performance

Shares of ORKA stock traded down $0.40 during trading hours on Thursday, hitting $62.78. The company had a trading volume of 672,780 shares, compared to its average volume of 1,031,509. The company’s fifty day moving average is $54.01 and its 200 day moving average is $38.92. Oruka Therapeutics has a fifty-two week low of $8.91 and a fifty-two week high of $91.00. The stock has a market capitalization of $3.15 billion, a PE ratio of -33.59 and a beta of -0.20.

Insider Activity at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,641 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $40.91, for a total transaction of $312,593.31. Following the sale, the insider directly owned 33,377 shares of the company’s stock, valued at $1,365,453.07. This represents a 18.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Lawrence Otto Klein sold 1,729 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $41.30, for a total transaction of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 23,765 shares of company stock worth $1,089,745. Company insiders own 23.49% of the company’s stock.

Institutional Investors Weigh In On Oruka Therapeutics

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. purchased a new position in shares of Oruka Therapeutics in the 1st quarter valued at $2,505,000. JPMorgan Chase & Co. grew its position in shares of Oruka Therapeutics by 567.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 15,425 shares of the company’s stock valued at $173,000 after buying an additional 13,115 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics in the 2nd quarter valued at $28,000. Rhumbline Advisers purchased a new position in shares of Oruka Therapeutics in the 2nd quarter valued at $320,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Oruka Therapeutics in the 2nd quarter valued at $96,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have commented on ORKA shares. Leerink Partners set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, April 30th. Guggenheim set a $200.00 price objective on shares of Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 27th. UBS Group increased their price objective on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. BTIG Research restated a “buy” rating and issued a $151.00 target price on shares of Oruka Therapeutics in a research note on Thursday. Finally, Stifel Nicolaus increased their price objective on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $120.80.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.